Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios
Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.
You may also be interested in...
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
ReWalk plans to use the proceeds to fund sales, R&D and reimbursement expenses related to its ReStore and Personal 6.0 devices as it continues to face negative effects of pandemic.
Brainlab is expanding its digital surgery portfolio with the FDA clearance for imaging and alignment module systems.